SV2017005520A - Derivados de tetrahidropiranil benzamida - Google Patents
Derivados de tetrahidropiranil benzamidaInfo
- Publication number
- SV2017005520A SV2017005520A SV2017005520A SV2017005520A SV2017005520A SV 2017005520 A SV2017005520 A SV 2017005520A SV 2017005520 A SV2017005520 A SV 2017005520A SV 2017005520 A SV2017005520 A SV 2017005520A SV 2017005520 A SV2017005520 A SV 2017005520A
- Authority
- SV
- El Salvador
- Prior art keywords
- tetrahidropiranil
- benzamida
- derivatives
- compounds
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE LA FÓRMULA SIGUIENTE: (VER FORMULA); EN DONDE R, R1-R3 SON COMO SE DESCRIBEN EN LA PRESENTE; MÉTODOS PARA TRATAR PACIENTES POR DIABETES USANDO LOS COMPUESTOS, Y PROCESOS PARA PREPARAR LOS COMPUESTOS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/073563 WO2016138631A1 (en) | 2015-03-03 | 2015-03-03 | Imidazo benzamide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005520A true SV2017005520A (es) | 2018-08-27 |
Family
ID=56849060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005520A SV2017005520A (es) | 2015-03-03 | 2017-08-22 | Derivados de tetrahidropiranil benzamida |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10196385B2 (es) |
| EP (1) | EP3265460A4 (es) |
| JP (1) | JP2018507232A (es) |
| KR (1) | KR20170106483A (es) |
| CN (1) | CN107406436B (es) |
| AU (1) | AU2016228055B2 (es) |
| BR (1) | BR112017015448A2 (es) |
| CA (1) | CA2975413A1 (es) |
| CL (1) | CL2017002148A1 (es) |
| CO (1) | CO2017008721A2 (es) |
| CR (1) | CR20170354A (es) |
| DO (1) | DOP2017000196A (es) |
| EA (1) | EA201791745A1 (es) |
| EC (1) | ECSP17058071A (es) |
| IL (1) | IL253405A0 (es) |
| MA (1) | MA41641A (es) |
| MX (1) | MX2017011087A (es) |
| PE (1) | PE20171650A1 (es) |
| PH (1) | PH12017501560A1 (es) |
| SG (1) | SG11201706718RA (es) |
| SV (1) | SV2017005520A (es) |
| TN (1) | TN2017000372A1 (es) |
| WO (2) | WO2016138631A1 (es) |
| ZA (1) | ZA201704948B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018014337A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | 3-Chloro-N- [ (1R, 3S) -3- [5- (3, 5-dimethylimidazol-4-yl) -4H-1, 2, 4-triazol-3-yl] cyclohexyl] -N-methyl-benzamide |
| CN111902413B (zh) | 2018-03-09 | 2023-10-17 | 里科瑞尔姆Ip控股有限责任公司 | 取代的1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505957A (ja) | 2006-10-10 | 2010-02-25 | アムゲン インコーポレイティッド | 糖尿病に対して使用されるｎ−アリールピラゾール化合物 |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| JP5685181B2 (ja) * | 2009-03-05 | 2015-03-18 | 塩野義製薬株式会社 | Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体 |
| EP2523558A4 (en) * | 2010-01-15 | 2013-06-19 | Merck Sharp & Dohme | BETA-CARBOLINE OXADIAZOLE DERIVATIVES AS ANTIDIABETIC COMPOUNDS |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| WO2015120610A1 (en) | 2014-02-14 | 2015-08-20 | Eli Lilly And Company | Gpr142 agonist compound |
-
2015
- 2015-03-03 WO PCT/CN2015/073563 patent/WO2016138631A1/en active Application Filing
-
2016
- 2016-02-18 MA MA041641A patent/MA41641A/fr unknown
- 2016-02-19 CR CR20170354A patent/CR20170354A/es unknown
- 2016-02-19 US US15/118,295 patent/US10196385B2/en active Active
- 2016-02-19 JP JP2017546161A patent/JP2018507232A/ja active Pending
- 2016-02-19 MX MX2017011087A patent/MX2017011087A/es unknown
- 2016-02-19 BR BR112017015448A patent/BR112017015448A2/pt not_active IP Right Cessation
- 2016-02-19 PE PE2017001456A patent/PE20171650A1/es not_active Application Discontinuation
- 2016-02-19 WO PCT/CN2016/074083 patent/WO2016138821A1/en active Application Filing
- 2016-02-19 AU AU2016228055A patent/AU2016228055B2/en not_active Expired - Fee Related
- 2016-02-19 CN CN201680013049.8A patent/CN107406436B/zh active Active
- 2016-02-19 EP EP16758437.4A patent/EP3265460A4/en not_active Withdrawn
- 2016-02-19 TN TNP/2017/000372A patent/TN2017000372A1/en unknown
- 2016-02-19 EA EA201791745A patent/EA201791745A1/ru unknown
- 2016-02-19 SG SG11201706718RA patent/SG11201706718RA/en unknown
- 2016-02-19 KR KR1020177024303A patent/KR20170106483A/ko not_active Application Discontinuation
- 2016-02-19 CA CA2975413A patent/CA2975413A1/en not_active Abandoned
-
2017
- 2017-07-10 IL IL253405A patent/IL253405A0/en unknown
- 2017-07-20 ZA ZA2017/04948A patent/ZA201704948B/en unknown
- 2017-08-21 DO DO2017000196A patent/DOP2017000196A/es unknown
- 2017-08-22 SV SV2017005520A patent/SV2017005520A/es unknown
- 2017-08-23 CL CL2017002148A patent/CL2017002148A1/es unknown
- 2017-08-28 CO CONC2017/0008721A patent/CO2017008721A2/es unknown
- 2017-08-30 PH PH12017501560A patent/PH12017501560A1/en unknown
- 2017-09-01 EC ECIEPI201758071A patent/ECSP17058071A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017501560A1 (en) | 2018-02-05 |
| CO2017008721A2 (es) | 2018-01-05 |
| AU2016228055B2 (en) | 2018-06-07 |
| KR20170106483A (ko) | 2017-09-20 |
| TN2017000372A1 (en) | 2019-01-16 |
| CN107406436A (zh) | 2017-11-28 |
| PE20171650A1 (es) | 2017-11-13 |
| IL253405A0 (en) | 2017-09-28 |
| EP3265460A1 (en) | 2018-01-10 |
| US20180194755A1 (en) | 2018-07-12 |
| MX2017011087A (es) | 2017-11-10 |
| EP3265460A4 (en) | 2018-08-08 |
| JP2018507232A (ja) | 2018-03-15 |
| DOP2017000196A (es) | 2017-09-15 |
| CA2975413A1 (en) | 2016-09-09 |
| CR20170354A (es) | 2017-09-05 |
| WO2016138631A1 (en) | 2016-09-09 |
| ECSP17058071A (es) | 2017-10-31 |
| SG11201706718RA (en) | 2017-09-28 |
| ZA201704948B (en) | 2019-02-27 |
| US10196385B2 (en) | 2019-02-05 |
| BR112017015448A2 (pt) | 2018-01-30 |
| EA201791745A1 (ru) | 2018-01-31 |
| CL2017002148A1 (es) | 2018-04-13 |
| AU2016228055A1 (en) | 2017-08-17 |
| WO2016138821A1 (en) | 2016-09-09 |
| MA41641A (fr) | 2018-01-09 |
| CN107406436B (zh) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| ECSP15045801A (es) | Inhibidores de la phd de 6(5hidroxi1hpirazol1il)nicotinamida | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| ECSP16073190A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
| GT201400187A (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| ECSP15008851A (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| BR112017017396A2 (pt) | derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos | |
| BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
| GT201400063A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
| CU24408B1 (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
| CU24608B1 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos | |
| CR20140400A (es) | Terapia combinada para el tratamiento del cancer de ovario | |
| GT201400169A (es) | Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2 | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. | |
| DOP2016000211A (es) | Pirazinas moduladoras de gpr6 | |
| BR112017016333A2 (pt) | compostos anticâncer | |
| SV2017005520A (es) | Derivados de tetrahidropiranil benzamida | |
| CO2017007074A2 (es) | Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina | |
| MX2020004871A (es) | Derivados de acido cafeico y sus usos. | |
| BR112017018992A2 (pt) | processo de preparação de derivados de fenilisoxazolina substituída |